Herbal Medicines for Liver Diseases (original) (raw)
References
Thyagrajan SP, Jayaram S, Gopalakrishnan V, Han R, Jayakumar P, Sripathi MS: Herbal medicines for liver diseases in India. J Gastroenterol Hepatol 17:S370–S376, 2002 ArticlePubMed Google Scholar
Schuppan D, Jia J-D, Brinkhaus B, Hahn EG: Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30:1099–1104, 1999 ArticlePubMed Google Scholar
Dhiman RK: Herbal hepatoprotective agents: marketing gimmick or potential therapies? Trop Gastroenterol 24:160–162, 2003 PubMed Google Scholar
Woolf SH, Sox HC Jr: The Expert Panel on Preventive Services: continuing the work of the U.S.Preventive Services Task Force. Am J Prev Med 7:326–330, 1991 PubMed Google Scholar
Venkateswaran PS, Millman I, Blumberg BS: Effects of an abstract of Phyllanthus niuri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 84:274–278, 1987 PubMed Google Scholar
Ott M, Thayagrajan SP, Gupta S: Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 27:908–915, 1997 ArticlePubMed Google Scholar
Lee CD, Ott M, Thyagarajan SP, Sharfritz DA, Burk RD, Gupta S: Phyllanthus amarus down regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest 24:161–168, 1996 Google Scholar
Polya GM, Wang BH, Foo LY: Inhibition of signal regulated protein kinases by plant derived hydrolyzable tannins. Phytochemistry 38:307–314, 1995 ArticlePubMed Google Scholar
Thyagarajan SP, Subramanian S, Thirunaksundari T, Venkateswaran PS, Blumberg BS: Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 2:764–766, 1988 ArticlePubMed Google Scholar
Thyagrajan SP, Jayaram S, Valliammae T, Madangopalan N, Pal VG, Jayaraman K: Phyllanthus amarus and hepatitis B. Lancet 336:949–950, 1990 Article Google Scholar
Thyagarajan SP, Jayaram S, Panneeselvam A, et al.: Effect of Phyllanthus amarus, an Indian medicinal plant on healthy carriers of hepatitis B virus. Results of six clinical trials. Indian J Gastroenterol 18 (Suppl 1):S26, 1999 (abstr) Google Scholar
Liu J, Lin H, McIntosh H: Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat 8:358–366, 2001 ArticlePubMed Google Scholar
Jadad AR, Moore A, Carroll D, et al.: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1–12, 1996 ArticlePubMed Google Scholar
Leelarasamee A, Trakulsomboon S, Maunwongyathi P, Somanabandhu A, Pidetcha P, Matrakool B, Lebnak T, Ridthimat W, Chandanayingyong D: Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Lancet 335:1600–1601, 1990 ArticlePubMed Google Scholar
Wang M, Zhou HB, Zhao GI, Zhao S, Mai K: Phyllanthus amarus cannot eliminate HBsAg in chronic B virus infection. Hepatology 21:22–24, 1991 Google Scholar
Berk L, de Man RA, Schalm SW, Labadie RP, Heijtink RA: Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed. J Hepatol 12:405–406, 1991 ArticlePubMed Google Scholar
Thamlikitkul V, Wasuwat S, Kanchanapee P: Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. J Med Assoc Thai 74:381–385, 1991 PubMed Google Scholar
Milne A, Hopkirk N, Lucas CR, Waldon J, Foo Y: Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. NZ Med J 107:243, 1994 Google Scholar
Luper S: A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 3:410–421, 1998 PubMed Google Scholar
Feher J, Lang I, Nekam KJ, Gergely P, Muzes G: In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai Exp Clin Med 15:129–134, 1990 Google Scholar
Campos R, Garrido A, Guerra R, Valenzuela A: Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 55:417–419, 1989 PubMed Google Scholar
Pietrangelo A, Borrella F, Casalgraudi G, et al.: Antioxidant activity of slilybin in vivo during long-term iron overload in rats. Gastroenterology 109:1941–1949, 1995 ArticlePubMed Google Scholar
Boigk G, Stroedter I, Herbst H, Waldschmidt J, Riecken EO, Schuppan D: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649, 1997 PubMed Google Scholar
Tuchweber B, Sieck R, Trost W: Prevention of silybin of phalloidin induced acute hepatoxicity. Toxicol Appl Pharmacol 51:265–275, 1979 ArticlePubMed Google Scholar
Faulstich H, Jahn W, Wieland T: Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung 30:452–454, 1980 PubMed Google Scholar
Jacobs BP, Dennehy C, Ramirej G, Sapp J, Lawrence VA: Milk thistle for the treatment of liver diseases: a systematic review and meta-analysis. Am J Med 113:506–515, 2002 ArticlePubMed Google Scholar
Seef LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH: Complementary and alternative medicine in chronic liver disease. Hepatology 34:595–603, 2001 ArticlePubMed Google Scholar
van Rossum TG, Vulto AG, de Man RA, Browner JT, Schalm SW: Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment pharmacol Ther 12:199–205, 1998 ArticlePubMed Google Scholar
Yoshikawa M, Matsui Y, Kawamoto H, et al.: Effects of glycyrrhizin on immune mediated cytotoxicity. J Gastroenterol Hepatol 12:243–247, 1997 PubMed Google Scholar
Miyaji C, Miyakawa R, Watanabe H, Kawamura H, Abo T: Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int Immunopharmacol 2:1079–1086, 2002 ArticlePubMed Google Scholar
Shiki Y, Shinai K, Satto Y, Yoshida S, Mosi Y, Wakashin M: Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrance antibody. J Gastroenterol Hepatol 7:12–16, 1992 PubMed Google Scholar
Abe N, Ebina T, Ishida N: Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 26:535–539, 1982 PubMed Google Scholar
Abe Y, Ueda T, Kato T, Kohli Y: Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 52:1817–1822, 1994 PubMed Google Scholar
Zhang L, Wang B: Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res 24:220, 2002 ArticlePubMed Google Scholar
Miyake K, Tango T, Ota Y, et al.: Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. J Gastroenterol Hepatol 17:198–204, 2002 Article Google Scholar
Iino S, Tango T, Matsushima T, Toda G, Miyake K, Hino K, Kumada H, Yasuda K, Kuroki T, Hirayama C, Suzuki H: Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 19:31–40, 2001 ArticlePubMed Google Scholar
Kumada H: Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 (Suppl 1):94–100, 2002 ArticlePubMed Google Scholar
Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494–1500, 1997 ArticlePubMed Google Scholar
Acharya SK, Dasarathy S, Tandon A, Joshi YK, Tandon BN: A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res 98:69–74, 1993 PubMed Google Scholar
Tandon A, Tandon BN, Bhujwala RA: Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol Res 23:55–61, 2002 ArticlePubMed Google Scholar
Acharya SK, Dasarathy S, Panda SK, Joshi YK: Parenteral glycyrrhozin therapy (Stronger Neominophegen C) in patients with subacute hepatic failure (SHF), chronic hepatitis (CH) and cirrhosis with activity. Final report on the ICMR Force Project, Apr 4, 1992, Mar 31, 1997
Tandon BN, Joshi YK, Acharya SK: Subacute liver failure. Natl Med J India 1:124–127, 1988 Google Scholar
Anand AC, Seth AK, Nagpal A, Varma PP, Gadela SR, Baliga KV, Chopra GS: Ribavirin plus glycyrrhizin is more effective than ribavirin monotherapy in renal allograft recipients with chronic hepatitis C (Abstr). Indian J Gastroenterol 23:S7, 2004 Google Scholar
Takeda R, Morimoto S, Uchida K, Nakai T, Miyamoto M, Hashiba T, Yoshimitsu K, Kim KS, Miwa U: Prolonged pseudoaldosteronism induced by glycyrrhizin. Endocrinol Japan 26:541–547, 1979 Google Scholar
Epstein M, Espiner E, Donald R, Hughes H: Effects of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J 1:488–490, 1977 PubMed Google Scholar
Sandhir R, Gill KD: Hepatoprotective effects of Liv 52 on ethanol induced liver damage in rats. Indian J Exp Biol 37:762–766, 1999 PubMed Google Scholar
Pandey S, Gujrati VR, Shanker K, Singh N, Dhawan KN: Hepato protective effect of Liv-52 against CCl4 induced lipid peroxidation in liver of rats. Indian J Exp Biol 32:674–675, 1994 PubMed Google Scholar
Gopumadhavan S, Jagadeesh S, Chauhan BL, Kulkarni RD: Protective effect of Liv 52 on alcohol-induced fetotoxicity. Alcohol Clin Exp Res 17:1089–1092, 1993 PubMed Google Scholar
Roy A, Soni GR, Kolhapure RM, Karnik UR, Patki PS: Down regulation of tumour necrosis factor activity in experimental hepatitis by a herbal formulation, Liv 52. Indian J Exp Biol 32:694–697, 1994 PubMed Google Scholar
Chauhan BL, Kulkarni RD: Effect of Liv 52, an herbal preparation, on absorption and metabolism of ethanol in humans. Eur J Clin Pharmacol 40:189–191, 1991 PubMed Google Scholar
Fleig WW, Morgan MY, Holzer MA, European Multicenter Study Group: The ayurvedic drug Liv 52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double blind, placebo controlled clinical trial. J Hepatol 26 (Suppl 1):127, 1997 (abstr) Google Scholar
de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran A, Fonseka MM, de Silva HJ: Liv 52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol 84:47–50, 2003 ArticlePubMed Google Scholar